Refine your search
Collections
Co-Authors
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Abd El Latif, Hemat K.
- Activity of Commonly Used Intravenous Nutrient and Bisolvon in Neonatal Intensive Care Units against Biofilm Cells and their Synergetic Effect with Antibiotics
Abstract Views :432 |
PDF Views:0
Authors
Affiliations
1 Department of Microbiology and Immunology Faculty of Pharmacy-Zagazig University- Zagazig-Egypt, EG
2 Department of Microbiology and Immunology Faculty of Pharmacy-Zagazig University-Zagazig-Egypt, EG
3 Department of Pediatrics Faculty of Medicine -Zagazig University-Zagazig-Egypt, EG
1 Department of Microbiology and Immunology Faculty of Pharmacy-Zagazig University- Zagazig-Egypt, EG
2 Department of Microbiology and Immunology Faculty of Pharmacy-Zagazig University-Zagazig-Egypt, EG
3 Department of Pediatrics Faculty of Medicine -Zagazig University-Zagazig-Egypt, EG
Source
Asian Journal of Pharmacy and Technology, Vol 3, No 2 (2013), Pagination: 81-90Abstract
The purpose of this study was to investigate the efficacy of intravenous nutrient(soluvit, vitalipid, aminoven infant, lipovenos) and bisolvon commonly used in neonatal intensive care units against biofilm cells of staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aerguinosa and klebseilla pneumonia as they are the most commonly isolated organisms and are biofilm producers. Also, the synergetic acticity of soluvit, heparin, bisolvon with antibiotics and its effect on minimum biofilm eradication concentration (MBEC) was tested. Intravenous nutrient and bromohexine are widely used in newborns. Numbers of viable cell count released from biofilm after treatment with intravenous nutrient and bromohexine were counted to compare the efficacy . The percentage of reduction in biofilm regrowth in case of using soluvit was 43-51% and 36-42 % for Gram positive and Gram negative respectively , on adding the vitalipid the percentage was 45-50 % and 37-41% for Gram positive and Gram negative respectively. While , in case of using bisolvon the percentage was 46-52% and 47-48% for Gram positive and Gram negative respectively. Adding lipovenos had a reduction percentage of 48-52% and 48-49% for Gram positive and Gram negative respectively. While , adding aminoven infant the percentage was 10-15% and 9-11% for Gram positive and Gram negative respectively. Adding soluvit , heparin and bisolvon to antibiotics had synergic effect . souvit with ciprofloxacin has 8-16 times decrease than minimum biofilm eradication concentration (MBEC) for ciprofloxacin alone . While, by adding soluvit to vancomycin the MBEC reduced by 16 times than MBEC of vancomycin alone . In case of combination soluvit with cefotaxime, amikacin and gentamycin the reduction in MBEC was 16 , 8 and 6-32 times respectively. The synergetic effect of adding heparin to ciprofloxacin , vancomycin , cefotaxime , amikacin and gentamicin was 2 times reduction with all except in case of gram negative the range of reduction was 0-2 with both gentamycin and ciprofloxacin. Bisolvon exihited synergetic effect with ciprofloxacin , vancomycin , cefotaxime , amikacin and gentamicin by 16, 32, 32, 8, 32-64 and 32 times decrease in MBEC respectively.Keywords
Biofilm, Neonatal Intensive Care Units, Bromohexine, Antibiofilm Agents, Intravenous NutrientReferences
- Lawn JE et al. Why are 4 million newborn babies dying each year? Lancet, 2004, 364:399–401.
- Maki, D.G.; Tambyah, P.A. Engineering out the risk of infection with urinary catheters. Emerging Infect. Dis. 2001, 7, 1-6.
- Schachter, B. Slimy business—the biotechnology of biofilms. Nat. Biotechnol. 2003, 21, 361-365.
- Costerton JW et al. Bacterial biofilms: a common cause of persistent infections. Science. 284; 1999: 1318–1322. 5. 5- Branda SS et al. Biofilms: The matrix revisited. Trends in Microbiology. 13; 2005: 20–26.
- Bjarnsholt T and Givskov M. Quorum-sensing blockade as a strategy for enhancing host defenses against bacterial pathogens. Philosophical Transactions of the Royal Society B 362; 2007:1213–1222.
- Hall-Stoodley L and Stoodley P. Evolving concepts in biofilm infections. Cell Microbiology. 11; 2009: 1034–1043.
- Naama Dror ; Mathilda Mandel ; Zadik Hazan and Gad Lavie: Advances in Microbial Biofilm Prevention on Indwelling Medical Devices with Emphasis on Usage of Acoustic Energy. Sensors 2009, 9, 2538-2554
- Branda, S.S.; Vik, A.S.; Friedman, L.; Kolter, R. Biofilms: the matrix revisited. Trends Microbiol.2005, 13.
- Parsek, M.R. Bacterial biofilms: an emerging link to disease pathogenesis. Annu. Rev. Microbiol.2003, 57, 677-701.
- Nichols, W.W.; Dorrington, S.M.; Slack, M.P.E.; Walmsley, H.L. Inhibition of tobramycin diffusion by binding to alginate. Antimicrob. Agents Chemother. 1988, 32, 518-523.
- Brown, M.R.W.; Allison, D.G.; Gilbert, P. Resistance of bacterial biofilms to antibiotics: a growth-rate related effect? J. Antimicrob. Chemother. 1988, 22, 777-783.
- Deighton MA, Capstick J, Domalewski E, van Nguyen T: Methods for studying biofilms produced by Staphylococcus epidermidis. Methods Enzymol 2001, 336:177-195.
- Yue Qu, Taghrid S. Istivan, Andrew J. Daley, Duncan A. Rouch and Margaret A. Deighton Comparison of various antimicrobial agents as catheter lock solutions: preference for ethanol in eradication of coagulase-negative staphylococcal biofilms . Journal of Medical Microbiology (2009), 58, 442– 450 .
- Clinical Laboratory Standards Institute (CLSI) (2010). Performance Standards for Antimicrobial Susceptibility Testing; twentieth Informational Supplement M100-S20vol.30 no.1 and Performance Standards for Antimicrobial Susceptibility Testing; twentieth Informational Supplement (June 2010 update) M100-S20-U, 3: 1.
- Lewis, K. 2000. Programmed death in bacteria. Microbiol. Mol. Biol. Rev. 64:503–514.
- Novak JS and Fratamico PM. Evaluation of ascorbic acid as a quorum-sensing analogue to control growth, sporulation, and enterotoxin production in Clostridium perfringens. Journal of Food Science. 69; 2004: 72–7
- Serry FME et al. The role of haemolysin transport system in antimicrobial resistance of haemolytic strains of Escherichia coli and the effect of potential efflux inhibitors. Journal of Pure and Applied Microbiology. 2; 2008: 307–318.
- Abbas Hisham A., Fathy M. Serry, Eman M. EL-Masry (2012) Combating Pseudomonas aeruginosa Biofilms by Potential Biofilm Inhibitors Asian J. Res. Pharm. Sci. 2012; Vol. 2: Issue 2, Pg 66-72.
- Arash Izadpanah, and Richard L. Gallo. Antimicrobial peptides Journal of the American Academy of Dermatology 2005; 52:381-90.
- Rinki Kapoor, Mayken W. Wadman, Michelle T. Dohm, Ann M. Czyzewski,Alfred M. Spormann, and Annelise E. Barron. Antimicrobial Peptoids Are Effective against Pseudomonas aeruginosa Biofilms Antimicrobial Agents And Chemotherapy, June 2011, p. 3054–3057.
- Ebner F, Heller A, Rippke F, Tausch I (2002) Topical use of dexpanthenol in skin disorders. Am J Clin Dermatol 3: 427– 433.
- Spry C, Kirk K, Saliba KJ(2008) Coenzyme A biosynthesis: an antimicrobial drug target. FEMS Microbiol Rev 32: 56–106.
- Grobben GJ, Chin-Joe I, Kitzen VA, Boels IC, Boer F, et al. (1998) Enhancement of exopolysaccharide production by Lactobacillus delbrueckii subsp. bulgaricus NCFB 2772 with a simplified defined medium. Appl Environ Microbiol 64: 1333–1337
- Ayman M. Noreddin, Ghada Sawy, Walid Elkhatib, Ehab Noreddin and Atef Shibl (2012) Inhibition of Adhesion and Invasion of Pseudomonas aeruginosa to Lung Epithelial Cells: A Model of Cystic Fibrosis InfectionLung Diseases - Selected State of the Art Reviews", book edited by Elvis Malcolm Irusen, ISBN 978-953-51-0180-2
- Patrick M. Schlievert, Marnie L. Peterson Glycerol Monolaurate Antibacterial Activity in Broth and Biofilm Cultures. PLoS ONE 2012 , Volume 7 ,Issue 7.
- Okuda Tamaki, Eitoyo Kokubu, Tomoko Kawana, Atsushi Saito, Katsuji Okuda, Kazuyuki Ishihara .Synergy in biofilm formation between Fusobacterium nucleatum and Prevotella species. Anaerobe 18 (2012) 110-116.
- Zhao T and Liu Y. N-acetyl cysteine inhibit biofilms produced by Pseudomonas aeruginosa. BMC Microbiology. 10; 2010: 140.
- Gordon CA et al. 1991. Use of slime dispersants to promote antibiotic penetration through the extracellular polysaccharide of mucoid Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 35; 1991: 1258–1260.
- Perez-Giraldo C et al. Influence of N-acetylcysteine on the formation of biofilm by Staphylococcus epidermidis. Journal of Antimicrobial Chemotherapy. 39; 1997: 643–646.
- Aslam S et al. Combination of tigecycline and Nacetylcysteine reduces biofilm-embedded bacteria on vascular catheters. Antimicrobial Agents and Chemotherapy. 51; 2007: 1556– 1558.
- Mansouri MD and Darouiche RO. In vitro antimicrobial activity of Nacetyl cysteine against bacteria colonizing central venous catheters. International Journal of Antimicrobial Agents. 29; 2007: 474–476.
- Mohamed M. Hafez & Mohammad M. Aboulwafa & Mahmoud A. Yassien & Nadia A. Hassouna Activity of some Mucolytics Against Bacterial Adherence to Mammalian Cells Appl Biochem Biotechnol DOI 10.1007/s12010-008-8312-2.
- J.P. Pintucci, S. Corno, M. Garotta Biofilms and infections of the upper respiratory tract. European Review for Medical and Pharmacological Sciences 2010; 14: 683-690.
- Krishnasami, Z., D. Carlton, L. Bimbo, M. E. Taylor, D. F. Balkovetz, J. Barker, and M. Allon. 2002. Management of hemodialysis catheter-related bacteremia with an adjunctive antibiotic lock solution. Kidney Int. 61:1136–1142.
- Rijnders, B. J., E. Van Wijngaerden, S. J. Vandecasteele, M. Stas, and W. E. Peetermans. 2005. Treatment of long-term intravascular catheter-related bacteraemia with antibiotic lock: randomized, placebo-controlled trial. J. Antimicrob. Chemother. 55:90–94.
- Trautner, B. W., and R. O. Darouiche. 2004. Catheterassociated infections: pathogenesis affects prevention. Arch. Intern. Med. 164:842–850.
- Robert M. Q. Shanks, Niles P. Donegan, Martha L. Graber, Sarah E. Buckingham, Michael E. Zegans, Ambrose L. Cheung, and George A. O’Toole: Heparin Stimulates Staphylococcus aureus Biofilm Formation. Infection And Immunity, Aug. 2005, p. 4596–4606